Issue
Alert me when new journal issues are available via or via
Masthead page iii Full-Text PDF (28 KB)
Editorial board page iv Full-Text PDF (62 KB)
Contents pages vii-viii Full-Text PDF (45 KB)
Original Articles
Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: Early results Kimberly A. Roehl, Scott E. Eggener, Stacy Loeb, Norm D. Smith, Jo Ann V. Antenor, William J. Catalona pages 465-471 Abstract | Full Text | Full-Text PDF (122 KB)
Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy John W. Robinson, Bryan J. Donnelly, Kerry Coupland, Jodi E. Siever, John C. Saliken, Cheryl Scott, P.M.A. Brasher, D. Scott Ernst pages 472-486 Abstract | Full Text | Full-Text PDF (631 KB)
Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma Lance C. Pagliaro, Cherie A. Perez, Shi-Ming Tu, Danai D. Daliani pages 487-491 Abstract | Full Text | Full-Text PDF (95 KB)
Improved prostate cancer detection with anterior apical prostate biopsies Jonathan L. Wright, William J. Ellis pages 492-495 Abstract | Full Text | Full-Text PDF (142 KB)
E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients He-Cheng Li, Jeffrey M. Albert, Eric T. Shinohara, Qiuyin Cai, Andrea Freyer, Hui Cai, Carolyn Cao, Zuofei Wang, Nobuhiko Kataoka, Ming Teng, Wei Zheng, Bo Lu pages 496-502 Abstract | Full Text | Full-Text PDF (657 KB)
Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer Mari Nakabayashi, Clair Beard, Sandra M. Kelly, David L. Carr-Locke, William K. Oh pages 503-508 Abstract | Full Text | Full-Text PDF (972 KB)
Seminar Section Introduction
Molecular markers of urologic cancers Robert H. Getzenberg page 509 Full Text | Full-Text PDF (41 KB)
Seminar Articles
Nucleic acid-based marker approaches to urologic cancers Robert W. Veltri, Danil V. Makarov pages 510-527 Abstract | Full Text | Full-Text PDF (232 KB)
Urinary bladder tumor markers Vinata B. Lokeshwar, Marie G. Selzer pages 528-537 Abstract | Full Text | Full-Text PDF (147 KB)
Molecular markers of prostate cancer Timothy J. Bradford, Scott A. Tomlins, Xiaoju Wang, Arul M. Chinnaiyan pages 538-551 Abstract | Full Text | Full-Text PDF (206 KB)
Survey section editorial board page 552 Full-Text PDF (35 KB)
Urologic Oncology Survey
Sunitinib in patients with metastatic renal cell carcinoma: Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY Michael L. Blute pages 553-554 Abstract | Full Text | Full-Text PDF (61 KB)
Clinical sequelae of radiographic iceball involvement of collecting system during computed tomography-guided percutaneous renal tumor cryoablation: Warlick CA, Lima GC, Allaf ME, Varkarakis I, Permpongkosol S, Schaeffer EM, Kavoussi LR, Jarrett TW, Solomon SB, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD Michael L. Blute page 554 Abstract | Full Text | Full-Text PDF (34 KB)
Fibrin sealant for retrograde ureteroscopic closure of urine leak after partial nephrectomy: French DB, Marcovich R, Department of Urology, University of Texas Health Science Center, San Antonio, TX Michael L. Blute pages 554-555 Abstract | Full Text | Full-Text PDF (41 KB)
Intermediate results of laparoscopic cryoablation in 59 patients at the Medical College of Wisconsin: Lawatsch EJ, Langenstroer P, Byrd GF, See WA, Quiroz FA, Begun FP, Departments of Urology and Radiology, Medical College of Wisconsin, Milwaukee, WI Michael L. Blute page 555 Abstract | Full Text | Full-Text PDF (36 KB)
The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer: Lamb GW, McMillan DC, Ramsey S, Aitchison M, Department of Urology, Gartnavel General Hospital, Glasgow, United Kingdom Michael L. Blute pages 555-556 Abstract | Full Text | Full-Text PDF (42 KB)
Open partial nephrectomy for tumor in a solitary kidney: Experience with 400 cases: Fergany AF, Saad IR, Woo L, Novick AC, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH Michael L. Blute page 556 Abstract | Full Text | Full-Text PDF (34 KB)
Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4–7 cm: Dash A, Vickers AJ, Schachter LR, Bach AM, Snyder ME, Russo P, Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY Michael L. Blute page 557 Abstract | Full Text | Full-Text PDF (36 KB)
Frequency and prognostic relevance of disseminated tumor cells in bone marrow of patients with metastatic renal cell carcinoma: Buchner A, Riesenberg R, Kotter I, Hofstetter A, Stief C, Oberneder R, Department of Urology, Klinikum Groshadern, Ludwig-Maximilians-University, Munich, Germany Michael L. Blute pages 557-558 Abstract | Full Text | Full-Text PDF (41 KB)
Evaluation of the nonneoplastic pathology in tumor nephrectomy specimens: Predicting the risk of progressive renal failure: Bijol V, Mendez GP, Hurwitz S, Rennke HG, Nose V, Department of Pathology and Laboratory Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA Paul Russo page 558 Abstract | Full Text | Full-Text PDF (35 KB)
Translocation carcinomas of the kidney after chemotherapy in childhood: Argani P, Lae M, Ballard ET, Amin M, Manivel C, Hutchinson B, Reuter VE, Ladanyi M, Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD Paul Russo pages 558-559 Abstract | Full Text | Full-Text PDF (40 KB)
Prospective study of safety margins in partial nephrectomy: Intraoperative assessment and contribution of frozen section analysis: Timsit MO, Bazin JP, Thiounn N, Fontaine E, Chretien Y, Dufour B, Mejean A, Department of Urology, Hôpital Necker-Enfants Malades, Paris, France Paul Russo pages 559-560 Abstract | Full Text | Full-Text PDF (42 KB)
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma: Ratain MJ, Eisen T. Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai A, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B. O’Dwyer PJ, University of Chicago, Chicago, IL Paul Russo page 560 Abstract | Full Text | Full-Text PDF (36 KB)
Pediatric renal cell carcinoma: Single institution 25 year case series and initial experience with partial nephrectomy: Cook A, Lorenzo AJ, Salle JL, Bakhshi M, Cartwright LM, Bagi D, Farhat W, Khoury A, Division of Urology and Department of Pathology, Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada Paul Russo page 561 Abstract | Full Text | Full-Text PDF (34 KB)
Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis: Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF, Department of Molecular Physiology, Mellon Prostate Cancer Institute, University of Virginia, Charlottesville, VA Yair Lotan pages 561-562 Abstract | Full Text | Full-Text PDF (42 KB)
Novel blood biomarkers of human urinary bladder cancer: Osman I, Bajorin DF, Sun T-T, Zhong H, Douglas D, Scattergood J, Zheng R, Han M, Marshall KW, Liew CC, Wayne Marshall and Choong-Chin Liew. New York University School of Medicine, New York, NY Yair Lotan pages 562-563 Abstract | Full Text | Full-Text PDF (42 KB)
A survivin gene signature predicts aggressive tumor behavior: Salz W, Eisenberg D, Plescia J, Garlick DS, Weiss RM, Wu XR, Sun TT, Altieri DC, Department of Cancer Biology and the Cancer Center, University of Massachusetts Medical School, Worcester, MA Yair Lotan pages 563-564 Abstract | Full Text | Full-Text PDF (43 KB)
Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma: Dhawan D, Hamdy FC, Rehman I, Patterson J, Cross SS, Feeley KM, Stephenson Y, Meuth M, Catto JW, Academic Urology Unit, University of Sheffield, and Department of Urology, Royal Hallamshire Hospital, UK Jer-Tsong Hsieh page 564 Abstract | Full Text | Full-Text PDF (36 KB)
Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells: Ben-Kasus T, Ben-Zvi Z, Marquez VE, Kelley JA, Agbaria R, Department of Clinical Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel Jer-Tsong Hsieh page 565 Abstract | Full Text | Full-Text PDF (35 KB)
Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor: Okegawa T, Nutahara K, Pong RC, Higashihara E, Hsieh JT. Department of Urology, University of Kyorin, Tokyo, Japan Jer-Tsong Hsieh pages 565-566 Abstract | Full Text | Full-Text PDF (43 KB)
Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder: Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ, Department of Urology, The New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY Jer-Tsong Hsieh pages 566-567 Abstract | Full Text | Full-Text PDF (39 KB)
Author/title index pages 568-571 Full-Text PDF (66 KB)
Subject index pages 572-579 Full-Text PDF (87 KB)
Information for Authors page CO3 Full-Text PDF (32 KB)
Copyright © 2010 Elsevier, Inc. All rights reserved | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
